PCSK9 inhibitors × lipids

TrialThe New England journal of medicine2020

Two Phase 3 Trials of Inclisiran in Patients with Elevated LDL Cholesterol.

Kausik K Ray et al.PubMed ↗Publisher ↗

What the trial testedrandomised · 1,617 people · 2020

Randomised comparison

Lowered lipids

−52.3percentage points−55.7 to −48.8

As reported

difference −52.3 %, 95% CI −55.7 to −48.8

Randomised comparison

Lowered lipids

−53.8percentage points−56.2 to −51.3

As reported

difference −53.8 %, 95% CI −56.2 to −51.3

Two numbers in the abstract

the abstract, start to end

reduced LDL cholesterol levels by 52.3% (95% confidence interval [CI], 48.8 to 55.7) in the ORION-10 trial and by 49.9% (95% CI, 46.6 to 53.1) in the ORION-11 trial, with corresponding time-adjusted reductions of 53.8% (95% CI, 51.3 to 56.2) and

← favours treatmentfavours comparator →
could be chance
Lipids
−52.3−55.7 to −48.8
Lipids
−53.8−56.2 to −51.3
PCSK9 inhibitorsLipids

PCSK9 inhibitors × lipidshelps?settled

unlikelylikely
0.930.93 without it
← favours treatmentfavours comparator →
this papermore certainless certain
1 / 5

703 papers cite itlatest 60 shown

2020
2025
2026
this paperpooled ittrialcites it

5 trials

Full record →Abstract, authors, funding and every citing paper · PMID 32187462